Evidence map›Paper›PMID 40603641›Full record

ArticleSurgery today2025

Association of visceral fat with unresectable/recurrent gastric cancer patients following chemotherapy: a propensity score-matched analysis.

Ryohei Nishiguchi, Takeshi Shimakawa, Shinichi Asaka, Masako Ogawa, Masano Sagawa, Kotaro Kuhara, Takebumi Usui, Hajime Yokomizo, Shunichi Shiozawa

Abstract read
PubMed Publisher
In one paragraph

Article in Surgery today, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ryohei NishiguchiDepartment of Surgery, Tokyo Women's Medical University Adachi Medical Center, 4-33-1 Kohoku, Adachi-ku, Tokyo, 123-8558, Japan. ryohei.nishiguchi@twmu.ac.jp.ORCID http://orcid.org/0000-0002-3967-4251
Takeshi ShimakawaDepartment of Surgery, Tokyo Women's Medical University Adachi Medical Center, 4-33-1 Kohoku, Adachi-ku, Tokyo, 123-8558, Japan.
Shinichi AsakaDepartment of Surgery, Tokyo Women's Medical University Adachi Medical Center, 4-33-1 Kohoku, Adachi-ku, Tokyo, 123-8558, Japan.
Masako OgawaDepartment of Surgery, Tokyo Women's Medical University Adachi Medical Center, 4-33-1 Kohoku, Adachi-ku, Tokyo, 123-8558, Japan.
Masano SagawaDepartment of Surgery, Tokyo Women's Medical University Adachi Medical Center, 4-33-1 Kohoku, Adachi-ku, Tokyo, 123-8558, Japan.
Kotaro KuharaDepartment of Surgery, Tokyo Women's Medical University Adachi Medical Center, 4-33-1 Kohoku, Adachi-ku, Tokyo, 123-8558, Japan.
Takebumi UsuiDepartment of Surgery, Tokyo Women's Medical University Adachi Medical Center, 4-33-1 Kohoku, Adachi-ku, Tokyo, 123-8558, Japan.
Hajime YokomizoDepartment of Surgery, Tokyo Women's Medical University Adachi Medical Center, 4-33-1 Kohoku, Adachi-ku, Tokyo, 123-8558, Japan.
Shunichi ShiozawaDepartment of Surgery, Tokyo Women's Medical University Adachi Medical Center, 4-33-1 Kohoku, Adachi-ku, Tokyo, 123-8558, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo clarify the association between visceral fat and the prognosis in patients with unresectable or recurrent gastric cancer following chemotherapy.

methodsA total of 118 patients were retrospectively analyzed and categorized into high- and low-visceral fat index (VFI) groups, using a cutoff value of 46.5 cm

resultsAfter matching, the high-VFI group demonstrated a significantly better OS and PFS than the low-VFI group. The ORR (40.6% vs. 15.6%, P = 0.026) and DCR (90.6% vs. 67.7%, P = 0.025) were significantly higher in the high-VFI group than the low-VFI group. The high-VFI group also showed a better nutritional status, longer S-1-based chemotherapy duration, higher transition rates to second-/third-line therapy, and fewer adverse events than the low-VFI group. A multivariate analysis identified VFI loss and target lesions (peritoneal and liver) as independent predictors of the OS, whereas VFI loss and target/non-target lesions were predictors of the PFS.

conclusionA high VFI was associated with an improved survival in patients with unresectable or recurrent gastric cancer by enhancing chemotherapy tolerance, reducing adverse events, and increasing the ORR and DCR.

Indexed as

Intra-Abdominal FatNeoplasm Recurrence, LocalPropensity ScoreStomach NeoplasmsAdultAgedDrug CombinationsFemaleHumansMaleMiddle AgedOxonic AcidPrognosisRetrospective StudiesSurvival RateTegafurDrug CombinationsOxonic AcidS 1 (combination)TegafurAdverse eventsChemotherapyUnresectable/recurrent gastric cancerVisceral fat

Identifiers

PMID40603641

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.